Industry Investment in HIV Vaccine Research

For the first AVAC Report, AVAC interviewed 23 companies with active or once-active HIV vaccine programs about the state of investment in the HIV vaccine research field. The take-home was that the HIV vaccine effort was not the aggressive, well-funded and coordinated international strategy but instead a patchwork of efforts. The report put forth five key recommendations, including a call for the US President to make development of a safe, effective and inexpensive vaccine by 2007, a national priority.

Tracking and Translating the Field